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Abstract
Purpose—Nonsteroidal anti-inflammatory drugs (NSAIDs) target the prostaglandin H synthase
enzymes, cyclooxygenase (COX)-1 and -2, and reduce colorectal cancer risk. Genetic variation in
the genes encoding these enzymes may be associated with changes in colon and rectal cancer risk
and in NSAID efficacy.
Methods—We genotyped candidate polymorphisms and tagSNPs in PTGS1 (COX-1) and
PTGS2 (COX-2) in a population-based case-control study (Diet, Activity and Lifestyle Study,
DALS) of colon cancer (n=1470 cases/1837 controls) and rectal cancer (n=583/775), and
independently among cases and controls from the Colon Cancer Family Registry (CCFR; colon n=
959/1535, rectal n= 505/839).
Results—In PTGS2, a functional polymorphism (−765G>C; rs20417) was associated with a 2-
fold increased rectal cancer risk (p=0.05) in the DALS study. This association replicated with a
significant nearly 5-fold increased risk of rectal cancer in the CCFR study (ORCC vs GG=4.88;
95%CI=1.54–15.45; ORGC vs GG=1.36; 95%CI: 0.95–1.94). Genotype-NSAID interactions were
observed in the DALS study for PTGS1 and rectal cancer risk, and for PTGS2 and colon cancer
risk, but were no longer significant after correcting for multiple comparisons and did not replicate
in the CCFR. No significant associations between PTGS1 polymorphisms and colon or rectal
cancer risk were observed.
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Conclusions—These findings suggest that polymorphisms in PTGS2 may be associated with
rectal cancer risk and impact the protective effects of NSAIDs.
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INTRODUCTION
Inflammation is thought to play a major role in the development and progression of
colorectal cancer. The use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as
aspirin reduces the risk of colorectal cancer (1). NSAIDs inhibit the prostaglandin H
synthase (PTGS) enzymes, which convert arachidonic acid into prostaglandins. Several
prostaglandins, primarily PGE2, have been implicated in colorectal carcinogenesis (2).
Although both PTGS isoforms, cyclooxygenase (COX)-1 and -2, catalyze the same reactions
and share approximately 60% amino acid identity, they are encoded by distinct genes and
differ substantially in their expression and regulation (3, 4). COX-1 is constitutively
expressed and is important for “housekeeping” functions, whereas COX-2 is typically an
inducible enzyme expressed in cells responding to inflammatory or proliferative stimuli (3).
Several lines of evidence indicate that COX-2 facilitates colorectal carcinogenesis. COX-2
is overexpressed in up to 90% of colon carcinomas and 40% of a precursor lesion, colorectal
adenoma (5–7). Aspirin decreases the risk of colorectal cancers that express high levels of
COX-2 but has little effect on the risk of tumors that have little or no COX-2 (8). Further, in
Min mice, selective inhibition of COX-2 or deletion of the PTGS2 gene results in a
substantial reduction in polyp development and tumorigenesis, providing evidence for
COX-2 involvement in carcinogenesis that is already at the stage of precursor lesions (9).
COX-2 has also been shown to activate co-carcinogens through oxidation [14].
There is also accumulating evidence to support the proposal (10) that COX-1, specifically
the platelet enzyme, is involved in colorectal tumorigenesis. First, there is the decreased
incidence and mortality of colorectal cancer that are associated with low doses of aspirin
(11), doses that selectively and persistently inhibit COX-1 in anucleate platelets (12). Oral
low-dose aspirin (80–100 mg) produces a transient pulse of the drug in the blood that peaks
at only 1–3 µM, with a t1/2 of ~20 min (13, 14). Given that aspirin’s IC50 for human COX-2
is ~15 µM (15, 16), low dose aspirin is likely to give little if any prolonged inhibition of
COX-2 activity in nucleated cells, which readily replace any acetylated COX-2 protein. A
second observation linking COX-1 to colorectal carcinogenesis is that knockout of the
PTGS1 gene markedly decreases the incidence of polyposis in Min mice (17). Thus, COX-1
and -2 appear to have distinct roles in colorectal carcinogenesis, and polymorphisms in the
genes encoding these enzymes (PTGS1 and PTGS2) might plausibly affect cancer risk. We
have previously shown that polymorphisms related to prostaglandin synthesis affect the risk
of colorectal adenoma and may modify the preventive associations with NSAID use (1, 18–
22). In the current analysis, we investigated PTGS1 and PTGS2 polymorphisms in relation
to the risk of colon and rectal cancer and their potential interactions with NSAID use in a
large population-based study of colon and rectal cancer risk, and validated those findings in
a second, independent, study. The results indicate that a PTGS2 functional promoter variant
is reproducibly associated with a two-to-four fold increased risk of rectal, but not colon,
cancer.
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Study Design and Data Collection
The analyses are based on a case/unrelated-control study of colon and rectal cancer and a
population-based case/unaffected-sibling-control study, here restricted to non-Hispanic
whites (NHW). Methods, described in detail elsewhere (23–27), are described briefly here.
Study population characteristics are in Table 1.
Diet, Activity and Lifestyle Study (DALS) colon and rectal cancer populations
(Discovery Study)—NHW colon cancer cases (n=1470) and controls (n=1837) and rectal
cancer cases (n=583) and controls (n=775) were recruited from Utah, the Northern
California Kaiser Permanente Medical Care Program (KPMCP), and metropolitan
Minneapolis-St. Paul, Minnesota (colon cases only). Eligible participants were aged 30–79
years with no previous diagnosis of colorectal cancer, familial adenomatous polyposis,
Crohn’s disease, or ulcerative colitis. Colon cancer cases were diagnosed between 1991 and
1994 (23), and rectal cancer cases between 1997 and 2001 (24, 25), respectively. Diet,
physical activity, smoking, anthropometry, medical history, NSAID use, family history of
cancer, demographics, race/ethnicity, and reproductive history data were obtained by
questionnaire (23, 24, 26, 28–32). The referent period for the study was two years prior to
diagnosis for cases and two years prior to selection for controls. NSAID use was defined as
aspirin/NSAID use at least three times per week for one month or more. The colon and
rectal cancer populations were recruited separately at different time periods, but are
collectively referred to in this manuscript as the DALS study as they were parallel study
designs.
Colon Cancer Family Registry study (Validation Study)—Participants were
recruited to the Colon Cancer Family Registry (CCFR) from six registry centers: University
of Hawaii, Honolulu, Hawaii, USA; Fred Hutchinson Cancer Research Center, Seattle,
Washington, USA; Mayo Clinic, University of Southern California Consortium (Dartmouth
Medical School, University of Southern California, University of Colorado, University of
Arizona, Cleveland Clinic Foundation, University of North Carolina and University of
Minnesota); Cancer Care Ontario, Toronto, Ontario, Canada and the University of
Melbourne, Victoria, Australia. Both population-based and clinic-based ascertainment
strategies were used (27), with some centers recruiting all incident cases from population-
based cancer registries (i.e. population-based recruiting), whereas others oversampled cases
with a family history of colorectal cancer or cases who were diagnosed at a young age (i.e.
family-based recruiting), as described in detail previously (27). The current study includes
only population-based participants. All cases were interviewed within five years of
diagnosis; 73% of cases were interviewed within two years of diagnosis. Standardized
questionnaires were used to collect epidemiologic data from study participants on
demographic characteristics, race/ethnicity, medical history, NSAID use, family history of
cancer, smoking history, selected diet, physical activity, height and weight, and, in women
only, reproductive history and hormone use. “Regular NSAID use” was defined as use of
aspirin or ibuprofen at least twice per week for one month or more (27, 33, 34). The CCFR
study used a case/unaffected-sibling-control design restricted to NHWs. Analyses of
population-based families included 1,464 cases and 2,374 unaffected siblings after exclusion
criteria were applied (see below). Cases included probands and affected relatives diagnosed
with primary invasive colorectal cancer from 1998–2002. Controls were siblings of cases
without a colorectal cancer diagnosis at the time of ascertainment. There were 1534 sibships
in our study. Because some sibships have multiple cases and/or controls, the number of
sibships can exceed the total number of cases.
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Sibships lacking either a case or an unaffected sibling, and cases for whom time-to-
interview was more than five years were excluded. Also excluded were individuals whose
samples were not available for genotyping, who did not have epidemiologic data, duplicate
samples, or who had missing genotypes. Informed consent was obtained from all
participants. This study was approved by the Institutional Review Board at each CCFR site.
Genotyping
For the DALS study, a linkage-disequilibrium (LD)-based tagSNP-selection algorithm (35)
was used to identify tagSNPs (r2=0.90, MAF>4%) representing common genetic variation in
PTGS1 and PTGS2 in the CEPH population (Utah residents with ancestry from northern and
western Europe) (36). We genotyped 19 polymorphisms in PTGS1, including 13 tagSNPs,
five candidate SNPs: R8W (rs1236913), P17L (rs3842787), R149L (rs10306140), L237M
(rs5789), and R108Q (rs5787); and one deletion polymorphism (L15–L16del) identified
previously through sequencing (37). PTGS2 polymorphisms included 15 tagSNPs and two
candidate SNPs from the promoter region: −765G>C (rs20417) and −163 C>G (rs5270).
The targeted polymorphisms are shown in Supplementary Table 1. Genotype quality control
and exclusion criteria were as described (21). To ensure adequate gene coverage, multiple
SNPs were genotyped from LD bins containing a large number of SNPs. After genotyping
was completed, redundant SNPs were removed from the analysis based on LD value
(r2>0.9) among NHW controls (Supplementary Figure 1). The CCFR study was genotyped
for 6 PTGS1 and 8 PTGS2 SNPs to provide independent validation of findings from the
DALS study. SNPs were chosen for the validation study if preliminary analyses in the
discovery dataset resulted in an unadjusted p-value <0.10. In addition, all candidate SNPs
were genotyped in the CCFR study unless they were monomorphic in the DALS study
(Supplementary Table 1). The p-value cutoff was determined during the preliminary
analyses of the DALS dataset, and chosen to minimize the number of false negative SNPs
from DALS while reducing the number of SNPs to be tested in the CCFR.
We used the Illumina™ GoldenGate assay to genotype blood-derived DNA in both the
DALS and CCFR studies. PTGS1 SNPs rs5789 (L237M) and rs1236913 (R8W) were
confirmed by Taqman allelic discrimination assay in the DALS colon cancer study. The
−765G>C polymorphism in PTGS2 (rs20417) was genotyped in the CCFR study using a
Taqman allelic discrimination assay (18). PTGS1 rs3842787 (P17L) and the L15–L16del
were genotyped by Sanger sequencing in all studies. Two PTGS1 tagSNPs that failed QC
and three candidate SNPs with a MAF <0.2%: R149L (rs10306140), R108Q (rs5787), −163
C>G (rs5270) were excluded from subsequent analysis (Supplementary Table 1).
Statistical analysis
Single SNP Main Effects—Odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated in the DALS study using unconditional logistic regression. Because of the case-
unaffected sibling control design for the CCFR, conditional logistic regression was used
with each sibling set treated as a matched set. All models were restricted to NHWs, as they
represented >90% of all study populations and the tagSNP-selection algorithm used was
based on the LD structure of the CEPH population, which has ancestry from northern and
western Europe. All models were adjusted for continuous age and sex. DALS models were
also adjusted for study site. “Main effects” analyses examined the association between each
individual SNP and colon or rectal cancer risk. For each of these analyses, likelihood ratio
tests (LRTs) were from a 2 degree of freedom (df) test where genotypes were modeled using
indicator variables for the heterozygous and the homozygous variant genotypes (co-
dominant models) and from a 1 df test where homozygous variant and heterozygous
genotypes were grouped for analysis (dominant models), which was the case only for SNPs
where fewer than ten cases or controls had the homozygous variant genotype. If fewer than
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five cases or controls had the heterozygous variant genotype, the statistical model was not
run. Significance was assessed using LRTs. All tests of statistical significance used a two-
sided p-value and α=0.05.
Interaction Analyses—Interactions were evaluated by taking the product of indicator
variables for NSAID use (current vs. never/former) and for genotypes. For SNP-NSAID
interactions a 2 df test was used to evaluate the multiplicative interaction term for co-
dominant SNPs and binary NSAID use (current vs. never/former) and a 1 df test was used to
evaluate the multiplicative interaction term for dominant SNPs and binary NSAID use.
Because use of NSAIDs may be associated with other known risk factors for CRC, NSAID
interactions were adjusted for additional variables within each study. DALS interactions
were additionally adjusted for the following continuous variables: BMI, smoking (cigarettes/
day), physical activity (hours/week), dietary calcium (mg/day), calories (kilocalories/day),
and dietary fiber (g/day). CCFR interactions were additionally adjusted for BMI
(continuous), smoking in pack-years (continuous), and physical activity (categorized from
average MET hours into inactive, less active, active, and very active). Aspirin use was also
investigated independently. To avoid small cell counts, the dominant model was used if
there were less than ten homozygous variant cases or controls in either NSAID category. If
fewer than five cases or controls had the heterozygous variant genotype in either NSAID
category, the statistical model was not run. Significance was assessed using likelihood ratio
tests (LRT). Table 3 includes only SNPs genotyped in both studies with a p-interaction less
than 0.05 in at least one study prior to any multiple testing corrections. The p-values
presented in Tables 2–4 are prior to correction for multiple testing. All analyses were
performed using SAS 9.3 or R version 2.13.2.
Multiple Testing Corrections—The DALS study was treated as the discovery data set
and multiple comparison corrected p-values were attained for all polymorphisms using minP
permutation tests with 10,000 replications (38). Candidate functional polymorphisms have
pre-specified hypotheses to impact cancer risk; therefore multiple testing corrections are not
necessarily applicable to those polymorphisms. The CCFR study served as an independent
validation data set and was not subject to multiple comparison correction in the primary
analyses. A secondary, post hoc multiple testing correction was performed in the CCFR
colon cancer study for genotype-NSAID interactions (Table 3).
RESULTS
Genetic associations
Characteristics (age, sex, site, NSAID use) of the DALS and CCFR study populations are
presented in Table 1. In our analysis, the DALS study served as the discovery dataset, and
the CCFR study was an independent validation dataset. Table 2 includes only SNPs that
were genotyped in both studies. After correcting for multiple comparisons, there were no
statistically significant (minP≤0.05) associations between SNPs in PTGS1 and risk of colon
or rectal cancer in the DALS discovery dataset (Table 2). The rare L15–L16 deletion did
show a trend towards increased risk in both the DALS and CCFR colon and rectal studies,
consistent with previous observations for adenoma (19), but this did not reach statistical
significance. Post hoc analyses combining colon and rectal cancers within each study also
did not reach significance for this polymorphism (data not shown).
In PTGS2, we observed a nearly two-fold increase in risk of rectal cancer in the DALS study
for individuals with the rs20417 CC genotype (−765 G>C, ORCC vs GG= 1.95; 95%CI: 0.89–
4.26; LRT p=0.05). Although this association was not significant after correcting for
multiple testing (minP>0.05), it did replicate in the independent CCFR study population,
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with a statistically significant (LRT p=0.01) increased risk of rectal cancer for individuals
with the GC or CC genotype (Table 2). Individuals with the CC genotype had an almost
five-fold increase in rectal cancer risk (ORCC vs GG = 4.88; 95% CI 1.54–15.45). A
comparison of rectal cancer risk for the homozygous variant CC genotype to the GG
common genotype resulted in p-value of 0.09 in the DALS study, and a p-value of 0.01 in
the CCFR study (data not shown). In both study populations, the increased risk was limited
to rectal cancer. A polytomous regression model found a significant difference between
colon and rectal cancer risk (global p<0.0001, data not shown) for this SNP in the DALS
study. There were no other statistically significant associations between PTGS2 SNPs and
risk of colon or rectal cancer in the DALS study.
NSAID Interactions
We observed nominally significant (LRT p ≤ 0.05) genotype-NSAID interactions for SNPs
in PTGS1 in the DALS discovery study (Table 3). First, the benefit of regular NSAID use
for reducing rectal cancer risk was limited to those with the PP (CC) genotype for P17L
(rs3842787; LRT p=0.05). This is consistent with our previous finding that the benefit of
regular NSAID use for reducing adenoma risk was limited to those with the PP genotype
(19). Additionally, we observed that NSAID use was of greater benefit for reducing rectal
cancer risk among those carrying the variant allele of either rs10306135 (4331 A>T, LRT
p=0.01) or rs6478565 (15268 A>G, LRT p=0.03). There is modest linkage disequilibrium
between these two SNPs, which may contribute to the similar findings (r2=0.56,
Supplementary Figure 1). These associations were no longer statistically significant after
correcting for multiple testing (minP>0.05), and did not replicate in the CCFR independent
validation study. No significant genotype-NSAID interactions were observed in PTGS1 in
relation to colon cancer risk. Aspirin use alone also showed no significant interactions with
PTGS1 genotypes for colon or rectal cancer in either study (data not shown).
For PTGS2, one significant genotype-NSAID interaction was seen in the DALS colon
cancer discovery dataset (rs20424; LRT p=0.01), but it was no longer significant after
correcting for multiple testing (minP>0.05), and did not replicate in the CCFR validation
study. No other significant genotype-NSAID interactions were observed in PTGS2 in the
DALS study.
Examination of aspirin use alone showed nominally significant associations with three SNPs
in PTGS2 in the DALS study (Supplementary Table 3). However, two of the three
interactions seen between PTGS2 genotype and aspirin use did not replicate in the CCFR
validation study. A third, rs2745557, had a significant interaction with aspirin use for rectal
cancer in the DALS study (int p=0.03) and for colon cancer in the CCFR study (int p=0.001)
but there was no association for rectal cancer in DALS or colon cancer in the CCFR. In both
studies, the variant allele carriers not currently taking aspirin were at increased risk
compared to wildtype non-users, but appeared to benefit more from aspirin than wildtype
individuals. No observed genotype-NSAID interactions reached statistical significance in
both the CCFR and DALS populations. Several genotype-NSAID interactions were
observed in the CCFR validation study but not in the DALS discovery study (Supplementary
Table 4) Associations observed in the CCFR validation study but not in the DALS discovery
study may be due to chance, inadequately controlling for interactions in the DALS discovery
study in the original analysis, or due to the sib-pair design of the CCFR study (39). To partly
address this, we performed an exploratory post hoc stratification of DALS by family history,
but were unable to replicate associations seen in the CCFR (data not shown). In addition,
statistically significant findings were typically limited to either colon or rectal cancer, but
not seen in both.
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We comprehensively assessed the importance of genetic variability in the two primary
prostaglandin synthesis genes, PTGS1 and PTGS2, using two independent study populations
of colon and rectal cancer risk. We describe a significant association between the rs20417
variant C allele in PTGS2 and increased risk of rectal cancer in DALS, a large population-
based study, which replicated in a second, independent, large population-based study of
rectal cancer from the CCFR. Genotype-NSAID interactions were observed in the DALS
study for PTGS1 and rectal cancer risk, and for PTGS2 and colon cancer risk; however,
these interactions were no longer statistically significant after correcting for multiple
comparisons and did not replicate in the CCFR validation study. Interactions between
aspirin use alone and PTGS2 genotypes were also inconsistent between the DALS and
CCFR studies.
The first report of an association between PTGS2 rs20417 and risk of colorectal cancer was
in a Japanese study (40), but other studies in Caucasian populations did not confirm the
finding (41, 42). Recent meta-analyses have indicated that the variant C allele may be a risk
factor for colorectal cancer in Asian but not in Caucasian populations (43–47). Importantly,
these earlier analyses did not examine colon and rectal cancer separately, and thus it is
unknown whether previous studies would have seen an association with rectal cancer risk in
Caucasians. In addition, large genome-wide association studies generally have not
genotyped rs20417 directly and also have not been stratified by colon and rectal cancer. As
our studies were restricted to NHWs, our results suggest that the rs20417 C allele may be a
risk factor for this group, but only for rectal cancer and not colon cancer. We have
previously reported a possible reduced risk of colorectal adenoma associated with this allele
in Caucasians, although sample sizes were too small to distinguish between adenomas in
colon and rectal sites (18).
We observed an interaction between this rs20417 SNP, NSAID use, and rectal cancer risk in
the CCFR study, where the variant C allele carriers had a greater protective benefit from
NSAID use. Observing statistically significant NSAID interactions in the CCFR and not in
the DALS may be due to chance, or may be due to differences in the study designs. As a
case/sibling-control study in which shared genetics and environment are matched between
siblings, the CCFR study is potentially more efficient for studying gene-environment
interactions (39), which could be one reason why this interaction was observed in the CCFR
but not in the DALS study. Alternatively, there could be confounding factors in the DALS
study that were not adequately controlled for in our analysis. We did not observe an
association between rs20417 and colon cancer risk in either study. A polytomous regression
model indicated that the difference in risk between colon and rectal cancer for rs20417 in the
DALS study was significant, with a global p <0.0001 for both main association and NSAID
interactions models (data not shown). In general, we saw little reproducibility in statistically
significant genetic associations between colon vs. rectal cancer risk.
These findings add further data to evidence that colon and rectal cancer have different
etiologies. In addition, a significant interaction between PTGS2 rs20417 and NSAID use
suggests that, in contrast to colorectal adenoma (18), rs20417 interacts with NSAIDs for
rectal cancer risk. The interaction was only seen in the CCFR, so this also could be a chance
finding. A study of colorectal cancer from Rotterdam reported that NSAID users carrying
the rs20417 C allele lived longer than non-users with the wildtype G allele (48). The
Rotterdam study did not see an association between colorectal cancer risk and rs20417
genotype, but they did not analyze colon and rectal cancer separately.
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COX-2, encoded by the PTGS2 gene, catalyzes a key step in the conversion of arachidonic
acid to bioactive prostaglandins. The PTGS2 candidate polymorphism, rs20417 (−765
G>C), is known to affect gene expression and prostaglandin production (49, 50). The
functional impact of rs20417 has been studied by several groups; their studies suggest a
proinflammatory effect of the CC genotype via increased prostanoids. A more than ten-fold
increase in PGE2 and PGD2 production was observed in monocytes from asthma patients
homozygous for rs20417 CC compared to monocytes from GG homozygotes, with
monocytes from heterozygotes displaying an intermediate phenotype of elevated PGE2 and
PGD2 (50, 51). This is consistent with the observation of increased urinary PGE2
metabolites and biomarkers of monocyte/macrophage activation in stable coronary artery
disease patients with the CC genotype (52). Further, AML patients have been found to have
increased PTGS2 mRNA levels in bone marrow and increased COX-2 protein levels in
serum (53). There has been a report of a 30% reduction in gene expression associated with
the CC variant in an initial study with a reporter-gene system (49). However, subsequent
findings were mixed (52), suggesting that in vitro models of promoter activity do not fully
capture the complex regulation of PTGS2 transcription.
We previously reported an increased adenoma risk for carriers of the PTGS1 L15–L16
deletion (19). The current analyses found similar trends for both colon and rectal cancer.
However, the trend is not statistically significant, possibly because this deletion is rare and
there is lack of power for validating the association. We also present a replication of our
previously reported genotype-NSAID interaction for the PTGS1 P17L polymorphism
(rs3842787). Consistent with our findings in colorectal adenoma (19), we found in the
DALS study that the NSAID-associated risk reduction for rectal cancer was limited to the
wildtype genotype for P17L. The functional impact of PTGS1 P17L (rs3842787) may be
direct, due to the amino acid change in the signal peptide, or indirect via the near-complete
linkage disequilibrium in Caucasians between rs3842787 and seven 5’ polymorphisms (54).
In general, statistically significant genotype-NSAID interactions did not replicate between
the DALS and CCFR studies. The one significant interaction seen in both studies, between
aspirin use and PTGS2 rs2745557, was inconsistent in that it was seen in rectal cancer in the
DALS study and in colon cancer in the CCFR study (Supplementary Table 3). This may be a
chance finding or may be due to these studies’ somewhat different study designs and
definitions of NSAID use, different adjustment variables, limited sample size and a weaker
NSAID effect in the CCFR (Table 1). Both DALS and CCFR are large population-based
case-control studies of colon and rectal cancer risk. The DALS study uses population-based
controls and the CCFR uses unaffected siblings as controls. This is both a strength and a
limitation of using the CCFR as a replication dataset for DALS. On one hand, the CCFR sib-
pair design helps avoid false positives that may result from population stratification and
increases the power to detect gene-NSAID interactions. The CCFR sib-pair design, under
which the shared genetics and environment are matched between siblings, can have greater
power to detect gene-environment interactions than a case-control study design (39). On the
other hand, the family-based study design may have reduced the power of the main effect
analyses. We felt that the potential benefit of the CCFR in replicating NSAID interactions
outweighed the limitations in the main-effect analysis. The main effects are adjusted for age
and sex in both studies. DALS is further adjusted for center, which is not necessary in the
CCFR due to the sib-pair design. For the NSAID analysis, both studies were also adjusted
for the known CRC risk factors of BMI, physical activity, and smoking. We were not able to
adjust the CCFR for dietary risk factors as such data are not available within the CCFR.
However, the additional adjustments to the DALS study did not substantially alter the
results. Larger-scale investigations are needed to address NSAID, and particularly aspirin,
pharmacogenetics with more certainty. Given the new results from randomized-controlled
Makar et al. Page 8













trials of aspirin, which demonstrated strong cancer preventive effects (1, 11, 55), this issue
deserves further attention.
CONCLUSIONS
One polymorphism in the PTGS2 gene (−765G>C; rs20417) was associated with a
statistically significantly increased risk of rectal cancer in two large, independent,
population-based studies in the US. Our results suggest that the rs20417 C allele may be a
risk factor for non-Hispanic whites, but only for rectal cancer, not colon cancer. No
significant associations were observed between the targeted PTGS1 polymorphisms and
colon or rectal cancer risk. A number of genotype-NSAID interactions were noted; however,
no genotype-NSAID interactions reached statistical significance in both the discovery and
validation studies or for both colon and rectal cancer. An interaction between rs2745557 in
PTGS2 and aspirin use was suggestive – showing similar gene-aspirin interaction patterns
and reaching significance in the DALS rectal cancer study and the CCFR colon cancer
study, but not vice versa. These findings suggest that further validation is needed.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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